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Abstract 
 
Drug resistance is a major problem for combating tuberculosis. Lack of 
understanding of how resistance emerges in bacteria upon drug treatment limits 
our ability to counter resistance. By analysis of the Mycobacterium tuberculosis 
interactome network, along with drug-induced expression data from literature, we 
show possible pathways for the emergence of drug resistance. To a curated set of 
resistance related proteins, we have identified sets of high propensity paths from 
different drug targets. Many top paths were upregulated upon exposure to anti-
tubercular drugs. Different targets appear to have different propensities for the 
four resistance mechanisms. Knowledge of important proteins in such pathways 
enables identification of appropriate ‘co-targets’, which when simultaneously 
inhibited with the intended target, is likely to help in combating drug resistance. 
RecA, Rv0823c, Rv0892 and DnaE1 were the best examples of co-targets for 
combating tuberculosis. This approach is also inherently generic, likely to 
significantly impact drug discovery. 
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Introduction 
Tuberculosis (TB) has remained one of the largest killer infectious diseases despite the 
availability of several chemotherapeutic agents and a vaccine [ 1]. The global burden of 
tuberculosis has taken a new dimension in the recent years due to the emergence of drug 
resistant varieties of Mycobacterium tuberculosis, besides synergy with HIV [ 2]. Global 
surveillance indicates that multi-drug resistant (MDR-TB) and extensively drug 
resistant TB (XDR-TB) is spreading to many countries and is posing a major threat to 
TB eradication programs [ 3, 4]. Several different strategies are being explored to counter 
the problem of resistance, which include rotation of antibiotic combinations, enhanced 
medical supervision to ensure patient compliance, identification of new targets that may 
be less mutable, search for new chemical entities for known targets, use of virulence 
factors as targets and ‘phenotypic conversion’, which aims to inhibit the resistance 
mechanism employed by the bacterium [ 5]. While each of these may be very important 
measures, available statistics indicate that resistant forms are still on the rise, warranting 
more research in the area. Of the different measures listed, the most cogent in its 
approach in the long term, is targeting the resistance mechanisms, since it enables 
confronting the problem at its source. However, in order to use this strategy effectively, 
it is at the outset, essential to understand the ways by which resistance can emerge upon 
exposure to a given drug.  
Studies on the molecular mechanisms of resistance to first line and second line 
antitubercular drugs have led to mapping of several mutations in the drug targets and the 
regulatory gene segments [ 3]. Besides these, the activation of the efflux pumps and 
drug-modifying enzymes are other known mechanisms of drug resistance [ 6]. Several 
studies in other organisms have reported the acquisition of drug-inactivating genes 
through horizontal gene transfer as a means of selection of the resistant variety [ 7]. It is 
clear from these that diverse mechanisms can exist for generating resistance and that the 
proteins involved in each can be quite remote from the drug targets in terms of their 
functional classes. It is important to study how, upon exposure to the specific drug 
molecule, information can flow from the target molecule to those that are involved in 
resistance. Knowledge of the molecular basis by which information flows from the 
specific drug target to the proteins elsewhere in the system relevant to drug resistance, 
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will help us address the issue of resistance in more systematic, rational and novel ways. 
With the availability of many genome-scale data from several studies, it is now feasible 
to address the issue of resistance from a systems perspective. Here, we use a proteome-
scale network of protein–protein connectivity to discover possible pathways that may be 
responsible for generating drug resistance. The network analyses reported here further 
help in classification of these paths based on known resistance mechanisms. The study 
also identifies controlling hubs within these paths and suggests proteins that could be 
explored for their use as drug co-targets. 
Results and Discussion 
Interactome network. A proteome-scale interaction network of proteins in 
M. tuberculosis H37Rv (Mtb) was derived (Table S1) from the STRING database [ 8], 
which includes interactions from published literature describing experimentally studied 
interactions as well as those from genome analysis using several well established 
methods such as domain fusion, phylogenetic profiling and gene neighborhood 
concepts. Thus, the network captures different types of interactions such as (a) physical 
complex formation between two proteins required to form a functional unit, (b) genes 
belonging to a single operon or to a common neighborhood, (c) proteins in a given 
metabolic pathway and hence influenced by each other, (d) proteins whose associations 
are suggested based on predominant co-existence, co-expressions, or domain fusion. 
This network represents a first comprehensive view of the connectivity among the 
various proteins, analogous to obtaining the road map of a city. With the methodology 
currently available, it is inevitable for a network of this type to contain some false 
positives as well as false negatives. To minimize this problem, all interactions tagged as 
‘low-confidence’ in the STRING database have been eliminated from this study. The 
considered network, despite its shortcomings, provides an excellent framework for 
navigating through the proteome. It also allows for refinement of the network upon the 
availability of new experimental data.  
Paths to Resistance. The network contains 3,925 nodes (proteins), with 29,664 
undirected edges (interactions) between them. The clustering coefficient of the network 
is 0.447. This high clustering coefficient is indicative of the high density of connections 
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in the network. Global views of the effects of antitubercular drugs on the mycobacterial 
proteome were obtained from the microarray experiments reported earlier; a list of 
genes whose expression levels were either increased or decreased upon exposure to the 
drugs was obtained for seven drugs, viz. isoniazid [ 9, 10], ethionamide [ 10], isoxyl, 
tetrahydrolipstatin, SRI-221, SRI-967 and SRI-9190 [ 9]. Known mechanisms relevant 
to resistance were classified into four types (a) efflux pumps, which transport drugs out 
of the cell, (b) cytochromes and other target modifying enzymes that could cause 
potential chemical modification of drug molecules, (c) SOS-response and DNA 
replication leading to mutations in the gene or its regulatory region, (d) proteins 
involved in horizontal gene transfer (HGT) to import a target modifying or detoxifying 
protein from its environment. We curated a list of 74 genes in the Mtb genome based on 
these mechanisms from published literature (Table 1). Among these, 12 cytochromes, 
out of the 36 present, five pumps (of 25), one HGT protein (of four) and three SOS 
proteins (of nine) were found to be upregulated in the expression profile corresponding 
to at least one of the seven drugs considered here.  
Proteins that were targets of the given drug(s) were grouped together as ‘source’ 
while the curated set of resistance proteins were grouped together as ‘sink’. Three of the 
drugs isoniazid, ethionamide and isoxyl are known to be inhibitors of mycolic acid 
biosynthesis, for which the 26 proteins of the mycolic acid pathway (MAP) [ 11] were 
used as source. It can be envisaged that upon inhibition of a protein in a given pathway, 
metabolic adjustments often occur so as to minimize the effect of inhibition on the 
particular protein [ 6]. In order to incorporate the effect of such adjustments, we have 
considered the whole pathway as the source rather than the individual protein. There are 
also reports in the literature that multiple proteins in MAP may be targeted by some of 
these drugs [ 12], making it important to consider the pathway as a whole. Shortest paths 
from source to the curated set of resistance proteins (sink) were computed. The set of 
shortest paths forms a network, consisting of 616 nodes and 1683 edges, which is 
referred to as the MAP-RES network hereafter (Fig. 1).  
The best ranked shortest paths to each of the four resistance mechanisms were 
identified as shown in Table 2 (complete list given in Table S2). High-scoring paths to 
each of the resistance mechanisms were observed from MAP (Fig. 2). However, paths 
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to SOS proteins top the list, followed by paths to cytochromes, while paths to HGT and 
pumps were of much lower rank. Nodes and edges that occur most frequently in a given 
set of paths are considered as node and edge hubs. Top edge-hubs in MAP-RES are listed 
in Table S3. Several of the nodes in these edge hubs also happen to be top node hubs. 
Some such edge hubs are MmaA4 (Rv0642c) – Rv0892, FabD (Rv2243) – FadA5 
(Rv3546), FadA5 (Rv3546) – Cyp125 (Rv3545c), Rv0049 – PcaA (Rv0470c), Rv0823c 
– DesA1 (Rv0824c), Acs (Rv3667) – Rv3779 and KasA (Rv2245) – RecA (Rv2737c). 
It is interesting to note that many of these edges can be attributed to metabolic 
linkages wherein the reactions involving the two proteins share a common metabolite 
(e.g. Rv0642 – Rv0892 or Rv0892 – Rv3801c). A few other edges could be attributed to 
adjacency of the genes in the genome whose transcription may be regulated by a 
common mechanism. A number of these proteins are also upregulated in the top paths 
(Figs. 1 & 2). In some cases, the entire paths were upregulated in one or more of the 
drugs, indicating the correlation of the identified paths with the observed expression 
profiles. A path from FabG4 (Rv0242c) to KasA (Rv2245) to RecA (Rv2737c), appears 
to be such a path, where all are upregulated, making the flow of information from 
source to sink that of high propensity. Another interesting path is from DesA1 
(Rv0824c)–Rv0823c–RecA (Rv2737c), which also has an alternate sub-path to RecA 
through RuvA (Rv2593c). In this path, besides RecA, Rv0823c is also upregulated 
(Fig. 2). Considering the individual functions of these molecules, it is easy to 
comprehend that the transcriptional regulator (Rv0823c) influenced by DesA1 
(Rv0824c), triggers the activation of RecA (Rv2737c), which while itself a sink, also 
activates many proteins such as DnaE1 (Rv1547), important for DNA synthesis. DesA1 
was earlier identified as a potential anti-tubercular drug target [ 11], by virtue of its 
critical role in mycolic acid biosynthesis [ 13]. Targeting RecA, DnaE1 or Rv0823c 
individually or together by chemotherapeutic agents along with DesA1, appears to be a 
good strategy to counter emergence of drug resistance. Thus RecA and DnaE1 could be 
considered as potential ‘co-targets’ for DesA1 and other MAP targets. All these three 
proteins are upregulated in response to one or more of the MAP inhibitors. 
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As many as 19 cytochrome proteins were found to be present in a tight cluster 
(Fig. 1), seven of them upregulated, connected to the MAP through Rv0892, which is 
annotated as a probable monooxygenase. Some noteworthy pathways across the four 
classes are: (i) Rv2243 (FabD) – Rv3546 (FadA5) – Rv3545c (Cyp125) (cytochrome); 
(ii) Rv2524c (Fas) – Rv2918c (GlnD) – Rv2890c (RpsB) – Rv3240c, the latter a 
translocase implicated in horizontal gene transfer; (iii) Rv2245 (KasA) – Rv1908c 
(KatG) – Rv1988 (a methyltransferase annotated as an efflux pump); (iv) Rv2245 
(KasA) – Rv2737c (RecA), Rv0904c (AccD3) – Rv1547 (DnaE1), both important for 
homologous recombination and DNA synthesis.  
In fact, RecA (Rv2737c) and a few other proteins such as SecA1 (Rv3240c), 
SahH (Rv3248c), Rv0892 and metK (Rv1392) occur in multiple resistance mechanisms, 
making their roles even more prominent in the emergence of resistance. Some of the 
MAP proteins such as KasA (Rv2245), FabD (Rv2243), which are upregulated, also 
appear to mediate multiple pathways across different resistance mechanisms. Proteins 
important for multiple resistance pathways could help in prioritizing ‘co-targets’. Of the 
top node and edge hubs in MAP-RES, it is of interest to note that nodes Rv0892 and 
Rv2243 are also among the top hubs in the entire STRING network, indicating their 
critical role in the Mtb interactome. Table S4 lists the nodes and edges in the STRING, 
ranked based on their betweenness.  
Table 2 also indicates shortest paths containing upregulated proteins in one or 
more of the four non-MAP drugs, used for obtaining the microarray data, along with the 
three MAP drugs discussed so far. It was observed that while paths to SOS still topped 
the list, many paths to cytochromes, pumps and HGT were found and contained a 
number of upregulated proteins, indicating that propensities for traversal of a path could 
vary from drug to drug. The other known targets of clinically used anti-tubercular drugs 
are RpoB (Rv0667) for rifampicin, the gyrase GyrA (Rv0006) for fluoroquinolones, cell 
wall biosynthesis proteins such as Alr (Rv3423c), DdlA (Rv2981c), Rv3792, EmbA 
(Rv3794) and EmbB (Rv3795) for cycloserine. With these targets as source, shortest 
paths were computed to the sink proteins. We observe that short high-scoring paths were 
observed from all targets examined to SOS involving many common nodes (e.g. DnaE1 
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(Rv1547), RecA (Rv2737)) whereas paths to other resistance mechanisms differed from 
target to target. Some edges in the SOS response (e.g. Rv2158c – Rv0631c) were 
common to paths from cell wall proteins and gyrase. From gyrase, SOS was the only 
predominant path, whereas from RpoB, paths to HGT and cytochromes were also 
among the top paths. For RpoB, many of the paths to SOS were mediated through Dcd 
(Rv0321), a DCTP deaminase. From cell wall proteins, paths to HGT and SOS top the 
list of high-scoring paths again, although there are also several paths to cytochromes. 
Paths to pumps were relatively fewer in number, in all cases. Of interest, however was a 
path to EfpA (Rv2846c), a transporter known to confer resistance to fluoroquinolones 
(Rv0006–Rv0524–Rv3065–Rv2846c), rifampicin and isoniazid resistance [ 6]. A higher 
scoring path to IniA (Rv0342) was observed through Rv0340 (conserved hypothetical 
protein), again agreeing well with previous reports based on transcription studies [ 14]. 
We also analyzed paths from proteins KatG (Rv1908c), EthA (Rv3854c) and PncA 
(Rv2043c), all known to transform prodrugs to the active drug species to the sink. It was 
interesting to observe that while EthA and PncA did not appear to have short paths to 
any of the resistance mechanisms, KatG had a direct interaction with an efflux pump 
(Rv1988, a probable methyltransferase, homologue of Erm37) and also several paths of 
two or fewer edges to all resistance mechanisms. In fact, studies on clinical isolates 
have shown mechanisms such as mutations in KatG, leading to loss of catalase activity, 
mutations in the promoter region of inhA, leading to its overexpression and mutations in 
InhA, leading to loss of affinity for isoniazid [ 3]. Paths to different resistance 
mechanisms for different drugs observed here, suggest that a given target may have a 
higher propensity for eliciting a specific mechanism of resistance, which when 
understood can be utilized to identify appropriate co-targets or secondary targets, to 
prevent emergence of resistance.  
Upon analysis of the network formed only by the upregulated proteins (Table S5), 
for each of the seven drugs, we observe that the network density is much higher, over an 
order of magnitude in most cases, than that of the whole interactome. This indicates that 
the upregulated genes have a higher influence on each other and more importantly their 
inter-relatedness is perhaps for a specific purpose. Such a purpose, if present, is non-
obvious by their functional classes or by a common analysis (such as co-expression) of 
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the microarray data, except in a few cases. However, when viewed in the context of the 
interaction networks, it becomes possible to analyze the outcome of such inter-
relatedness.  
Reports in literature indicate that the main strategies for adaptation by the bacillus 
in response to these drugs are mutations to reduce the bioavailability or the binding of 
these drugs to the MAP target(s). This inherently implies that the MAP proteins have a 
streamlined mechanism to pass on the information of drug inhibition (or lack of mycolic 
acid production) to the SOS proteins involved in recombination and DNA biosynthesis. 
A time course microarray data over a period of a few weeks from clinical samples 
would ideally have been required to see the expression patterns where resistance has 
emerged. Nevertheless, the existing data provides a first glimpse of the possible routes 
that might lead to resistance. Knowledge of the pathways leading to drug resistance will 
be of immense help in identifying appropriate co-targets, thus forming a new rational 
strategy for combating drug resistance. Given the rapid accumulation of various types of 
‘omics’ data, including comprehensive views of protein–protein interactions, this type 
of analyses is becoming feasible for many pathogenic organisms. Our approach is also 
inherently generic, lending itself to be utilized in any drug discovery program.  
Methods 
Interactome Network. A proteome-scale interaction network of proteins in Mtb was 
derived (Table S1) from the STRING database, using only the ‘high-confidence’ and 
‘medium-confidence’ data. 
Curation of Resistance Genes. We curated a list of 74 genes in the Mtb genome based 
on resistance mechanisms from published literature [ 6, 7, 15– 17, TubercuList web server 
(http://genolist.pasteur.fr/TubercuList/)] (Table 1). 
Betweenness. Betweenness is a centrality measure of a vertex within a graph [ 18]. For a 
graph G(V,E), with n vertices, the betweenness CB(v) of a vertex v is defined as 
( )( ) stB
s v t V st
vC v σ
σ≠ ≠ ∈
= ∑  
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where σst is the number of shortest paths from s to t, and σst(v) is the number of shortest 
paths from s to t that pass through a vertex v. A similar definition for ‘edge 
betweenness’ was given by Girvan and Newman [ 19]. Betweenness was calculated for 
all nodes and edges in STRING, ranking them to obtain a list of hubs (Table S4). 
Network analysis. Shortest paths from source to the curated set of resistance proteins 
(sink) were computed using the Dijkstra’s algorithm implemented in the MATLAB-
Boost Graph Library (David Gleich; http://www.stanford.edu/~dgleich/programs/matlab 
_bgl/). We added a weighting scheme to account for the frequency of the edge in the 
network, as well as to incorporate the upregulation information of the nodes forming a 
given edge. The weight of an edge AB is given as 
1
(1 )(1 )st st s t
w
f N N
=
+ +
 
where fst corresponds to the frequency of the edge between s and t, which is the number 
of times a given edge occurs in the set of paths, Ns and Nt refer to number of drugs (only 
drugs that target MAP are considered) for which node s and node t are upregulated 
respectively. Thus, the maximum possible score for an edge is unity, when the edge 
appears only once in the set of chosen paths and neither of the nodes forming the edge is 
upregulated. A path score was computed as the sum of the weighted scores for the edges 
in a path, from which the least scoring path corresponded to the highest rank. Cytoscape 
[ 20] was used for network visualizations.  
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Antibiotic efflux pumps [ 6, 15] 
PstB (Rv0933), Rv2686c, Rv2687c, Rv1688c, IniA (Rv0342), Mmr (Rv3065), Rv3239c, 
Rv3728, EfpA (Rv2846c), Rv1877, Rv2333c, Rv2459, Rv1410c, Rv1250, Rv1258c, EmrB 
(Rv0783c), Rv1634, Rv0849 
Rv0191, Rv0037c, Rv2456c, Rv2994 (hypothetical) [ 15] 
BlaC (Rv2068c) [Antibiotic degrading enzyme [ 6]]* 
Erm37 (Rv1988), WhiB7 (Rv3197A) [Target-modifying enzymes [ 16, 17]]* 
SOS and related genes [ 7] 
DnaE2 (Rv3370c), RuvA (Rv2593c), RecA (Rv2737c), RecB (Rv0630c), RecC (Rv0631c), 
RecD (Rv0629c), DnaE1 (Rv1547), PolA (Rv1629), LexA (Rv2720) 
Genes implicated in horizontal gene transfer [TubercuList, 7] 
SecA1 (Rv3240c), SecA2 (Rv1821), Rv3659c, Rv3660c 
Cytochromes [TubercuList] 
ccdA (Rv0527), CcsA (Rv0529), CtaB (Rv1451), CtaC (Rv2200c), CtaD (Rv3043c), CtaE 
(Rv2193), CydA (Rv1623c), CydB (Rv1622c), CydC (Rv1620c), CydD (Rv1621c), Cyp121 
(Rv2276), Cyp123 (Rv0766c), Cyp124 (Rv2266), Cyp125 (Rv3545c), Cyp126 (Rv0778), 
Cyp128 (Rv2268c), Cyp130 (Rv1256c), Cyp132 (Rv1394c), Cyp135A1 (Rv0327c), 
Cyp135B1 (Rv0568), Cyp136 (Rv3059), Cyp137 (Rv3685c), Cyp138 (Rv0136), Cyp139 
(Rv1666c), Cyp140 (Rv1880c), Cyp141 (Rv3121), Cyp142 (Rv3518c), Cyp143 (Rv1785c), 
Cyp144 (Rv1777), Cyp51 (Rv0764c), DipZ (Rv2874), LldD1 (Rv0694), LldD2 (Rv1872c), 
QcrB (Rv2196), QcrC (Rv2194), SdhC (Rv3316) 
Table 1: Curated list of resistance proteins  
*These proteins are antibiotic degrading and target modifying proteins, but since they are 
very few, have been included with the pumps for convenience  
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Path Score 
SOS   
Rv0242c -( 276)-> Rv2245 -( 596)-> Rv2737c 0.0102 
Rv0242c -( 276)-> Rv2245 -( 596)-> Rv2737c -( 44)-> Rv2720 0.0727 
Rv0904c -( 241)-> Rv1547 0.1000 
Rv0824c -( 162)-> Rv0823c -( 247)-> Rv2737c 0.1344 
Rv0242c -( 276)-> Rv2245 -( 596)-> Rv2737c -( 96)-> Rv2593c 0.1352 
Rv2246 -( 400)-> Rv1131 -( 526)-> Rv1629 0.1389 
CYTOCHROMES   
Rv2243 -( 200)-> Rv3546 -( 395)-> Rv3545c 0.0174 
Rv0242c -( 436)-> Rv2243 -( 200)-> Rv3546 -( 395)-> Rv3545c 0.0203 
Rv1350 -( 205)-> Rv2243 -( 200)-> Rv3546 -( 395)-> Rv3545c 0.0230 
Rv1483 -( 121)-> Rv2243 -( 200)-> Rv3546 -( 395)-> Rv3545c 0.0352 
Rv2243 -( 257)-> Rv0769 -( 558)-> Rv0766c 0.0643 
Rv0242c -( 436)-> Rv2243 -( 559)-> Rv2782c -( 513)-> Rv1622c 0.0655 
Rv0242c -( 436)-> Rv2243 -( 257)-> Rv0769 -( 558)-> Rv0766c 0.0673 
Rv0242c -( 436)-> Rv2243 -( 559)-> Rv2782c -( 578)-> Rv2193 0.0738 
Rv0643c -( 350)-> Rv0892 -( 350)-> Rv0568 0.0956 
Rv0643c -( 350)-> Rv0892 -( 350)-> Rv3059  0.0956 
ANTIBIOTIC EFFLUX PUMPS   
Rv2245 -( 565)-> Rv0340 -( 447)-> Rv0342 0.0526 
Rv0242c -( 276)-> Rv2245 -( 565)-> Rv0340 -( 447)-> Rv0342 0.0580 
Rv2243 -( 356)-> Rv2238c -( 569)-> Rv2687c 0.0901 
Rv2243 -( 2)-> Rv2245 -( 565)-> Rv0340 -( 447)-> Rv0342 0.1151 
Rv0642c -( 350)-> Rv3248c -( 486)-> Rv3240c -( 323)-> Rv3239c 0.1365 
Rv0642c -( 350)-> Rv3248c -( 350)-> Rv1988 0.1385 
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Rv1350 -( 90)-> Rv2245 -( 596)-> Rv2737c -( 429)-> Rv2882c -( 584)-> Rv0783c 0.3169 
Rv2245 -( 369)-> Rv1908c -( 350)-> Rv1988 0.3833 
Rv0242c -( 276)-> Rv2245 -( 369)-> Rv1908c -( 350)-> Rv1988 0.3888 
HORIZONTAL GENE TRANSFER   
Rv0644c -( 350)-> Rv3248c -( 486)-> Rv3240c 0.0812 
Rv2243 -( 202)-> Rv2925c -( 378)-> Rv3659c 0.0913 
Rv2243 -( 202)-> Rv2925c -( 378)-> Rv3659c -( 63)-> Rv3660c 0.1538 
Rv2245 -( 596)-> Rv2737c -( 514)-> Rv2890c -( 187)-> Rv3240c 0.3715 
Rv2524c -( 464)-> Rv2918c -( 380)-> Rv2890c -( 187)-> Rv3240c 0.4833 
Table 2: Top paths in the MAP-RES network.  
The weighted score for each path is shown. The nodes upregulated by MAP drugs are indicated in 
black boldface, while those that are upregulated by other drugs are indicated in grey boldface. The 
figures in parentheses indicate the edge weight; a lower edge weight indicates a higher confidence 
in the interaction. 
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Figure legends:  
Fig. 1: Illustration of the MAP-RES network depicting paths from MAP proteins to the 
curated set of resistance proteins. Nodes correspond to the individual proteins in the 
network while the edges indicate interactions between them. Each class of nodes is 
colored differently as indicated. Grey nodes indicate those that do not belong to any of 
the marked classes. The nodes are sized in proportion to the number of MAP drugs that 
induce its upregulation. The thickness of the edge is proportional to the number of times 
a shortest path is traversed through that edge.  
 
Fig. 2: Top scoring paths from MAP to each of the four resistance classes are shown. 
Nodes are labeled by their Rv IDs, as obtained from TubercuList. Nodes correspond to 
the individual proteins in the network while the edges indicate interactions between 
them. Each class of nodes is colored differently as indicated. Grey nodes indicate those 
that do not belong to any of the marked classes. The nodes are sized in proportion to the 
number of MAP drugs that induce its upregulation. The thickness of the edge is 
proportional to the number of times a shortest path is traversed through that edge. The 
dotted edge is not a high-scoring path but is of significance, as discussed in the text. 
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